The KNOP1 Knockout HT29 Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout population from the HT29 human colorectal adenocarcinoma line, featuring targeted disruption of the KNOP1 gene. This heterogeneous population collectively ensures loss of gene function while minimizing clonal artifacts, offering a robust model to study KNOP1-dependent processes.
The HT29 cell line is a widely used model of human colorectal adenocarcinoma, originally isolated from a grade II colonic tumor. These epithelial cells form adherent monolayers, express intestinal mucins, and maintain tight junction integrity, making them suitable for oncogenic studies and intestinal barrier analyses. HT29 cells carry common colorectal cancer mutations, including those in APC, KRAS, and TP53, and exhibit constitutive activation of Wnt and c-Myc pathways, providing a disease-relevant context.
KNOP1 is a nucleolar protein that functions as a direct transcriptional target of the c-Myc oncogene. In response to growth factors such as EGF, c-Myc upregulates KNOP1, which then associates with the nucleolar ribonucleoprotein complex containing NOP56, NOP58, and fibrillarin to facilitate pre-rRNA processing and ribosome assembly. Loss of KNOP1 disrupts ribosome biogenesis and can trigger nucleolar stress, characterized by ribosomal protein-mediated sequestration of Mdm2 and subsequent p53 activation. Through its role in ribosome production, KNOP1 thus promotes cell growth and proliferation downstream of Myc-driven anabolic metabolism.
In the HT29 context, knockout of KNOP1 abrogates a key link between Myc signaling and ribosome biogenesis, making these cells particularly useful for dissecting the reliance of colorectal tumors on elevated nucleolar activity. The HT29 line??s TP53 mutation and constitutive c-Myc activation provide a backdrop to investigate nucleolar stress pathways that may bypass p53 dysfunction. Additionally, the epithelial nature permits studies of how ribosome biogenesis impacts intestinal barrier integrity and carcinogenesis, bridging nucleolar biology with colorectal cancer pathophysiology.
This model enables investigation of c-Myc-driven tumorigenesis, nucleolar stress signaling, and colorectal cancer biology. Compatible assays include western blot and RT-qPCR for KNOP1 targets and nucleolar proteins, cell proliferation and colony formation assays, immunofluorescence staining of nucleolar markers such as fibrillarin, flow cytometry for cell cycle analysis, and RNA-seq for transcriptome-wide effects. The polyclonal cells are also suited for high-throughput drug screening for ribosome biogenesis inhibitors. For technical inquiries or ordering, please contact Ascent Research.
